-
Aug 20, 2024 | 
cancernetwork.com | Adam Brufsky |Xianchen Liu |Benjamin Li |Lynn McRoy |Doris Makari |Rachel M. Layman | +2 more
BackgroundCardiovascular diseases (CVDs) can impact breast cancer treatment selection and clinical outcomes. A CDK4/6 inhibitor combined with endocrine therapy (ET) is now the standard of care as a first-line treatment for patients with hormone receptor–positive (HR+)/HER2-negative (HER2–) metastatic breast cancer. However, the effectiveness data of CDK4/6 inhibitors in patients with metastatic breast cancer and CVD are limited.
-
Jun 24, 2024 | 
nature.com | Yeon Hee Park |David Sommerhalder |Kan Yonemori |Erika Hamilton |Toshinari Yamashita |Rachel M. Layman | +3 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig.
-
Jun 1, 2024 | 
nature.com | Yeon Hee Park |David Sommerhalder |Kan Yonemori |Erika Hamilton |Toshinari Yamashita |Rachel M. Layman | +3 more
AbstractInhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER+) breast cancer preclinical models. PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.
-
Aug 17, 2023 | 
onclive.com | Stephanie Graff |Rachel M. Layman
Transcript:Rachel Layman, MD: This has been a great conversation. I was curious, what up-and-coming things are you looking forward to in the adjuvant setting? Stephanie Graff, MD, FACP: In the adjuvant setting, I am excited about some of the trials that are going on that are going to be looking at questions around triple-negative breast cancer. I guess I can say that I kind of hate KEYNOTE 522 [NCT03036488]; it’s a lot of chemotherapy.
-
Aug 10, 2023 | 
onclive.com | Stephanie Graff |Rachel M. Layman
Transcript:Stephanie Graff, MD, FACP: With CDK4/6 inhibitors, many of the adverse events are class, and some of them are drug specific. As a class, CDK4/6 inhibitors have a black box warning for interstitial lung disease. I do tell patients that that’s a risk and I need them to be mindful of any changes in breathing, cough, or new pulmonary symptoms, and that [requires] an emergency call to me. Just make them aware of that potential risk. But it’s exceedingly rare.
-
Aug 10, 2023 | 
onclive.com | Stephanie Graff |Rachel M. Layman
Transcript:Rachel Layman, MD: If you were seeing her today, would you…Stephanie Graff, MD, FACP: … In a world where the FDA does not exist? Rachel Layman, MD: Right. What would you do? Stephanie Graff, MD, FACP: If she’s eligible for NATALEE [NCT03701334], I absolutely would talk to her.
-
Aug 3, 2023 | 
onclive.com | Stephanie Graff |Rachel M. Layman
Transcript:: Where monarchE [NCT03155997] included patients with 4 or more positive lymph nodes or patients with 1 to 3 positive lymph nodes and 1 additional risk factor—and I’m not going to list those right now—NATALEE [NCT03701334] included all patients with positive lymph nodes. Even N1, 1 to 3 positive lymph nodes, as well as patients with tumors greater than 2 cm, like T2 tumors, and an additional risk factor.
-
Aug 3, 2023 | 
onclive.com | Stephanie Graff |Rachel M. Layman
Transcript:Rachel Layman, MD: How would you approach this patient in regard to classifying her risk of recurrence? : This is another great case of a premenopausal patient who is at high risk for disease recurrence.
-
Jul 27, 2023 | 
onclive.com | Stephanie Graff |Rachel M. Layman
Transcript:Rachel Layman, MD: Let’s switch gears and talk about another case. I have a patient who is a 42-year-old premenopausal woman who presents to the clinic to discuss the management of screen-detected right breast cancer. She has an ECOG performance status of 1. Her past medical history is only significant for GERD [gastroesophageal reflux disease] and environmental allergies. Past surgical history, [was] just a tonsillectomy as a child.
-
Jul 27, 2023 | 
onclive.com | Stephanie Graff |Rachel M. Layman
Transcript:Stephanie Graff, MD, FACP: One thing I particularly avoided when I defined our case was her genetic testing. I left her paternal lineage undefined. Of course, they’re her patients with missed paternity, which is pretty common. Genetic testing is really important because you don’t know. I certainly, given her young age would have recommended genetic testing anyway. There’s a probability that she could have a genetic mutation.
